HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $113
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on BioNTech (NASDAQ:BNTX) and increased the price target from $107 to $113.
May 08, 2024 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioNTech's Buy rating is maintained by HC Wainwright & Co., with a raised price target from $107 to $113, indicating a positive outlook on the stock.
The increase in price target by HC Wainwright & Co. reflects a strong confidence in BioNTech's future performance. This endorsement from a reputable analyst is likely to positively influence investor sentiment and potentially lead to a short-term increase in BNTX stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100